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Abstract
Background: Osteoporosis affects over 200 million people worldwide at a high cost to healthcare systems.
Although guidelines on assessing and managing osteoporosis are available, many patients are not receiving
appropriate diagnostic testing or treatment. Findings from a systematic review of osteoporosis interventions, a
series of mixed-methods studies, and advice from experts in osteoporosis and human-factors engineering were
used collectively to develop a multicomponent tool (targeted to family physicians and patients at risk for
osteoporosis) that may support clinical decision making in osteoporosis disease management at the point of care.
Methods: A three-phased approach will be used to evaluate the osteoporosis tool. In phase 1, the tool will be
implemented in three family practices. It will involve ensuring optimal functioning of the tool while minimizing
disruption to usual practice. In phase 2, the tool will be pilot tested in a quasi-experimental interrupted time series
(ITS) design to determine if it can improve osteoporosis disease management at the point of care. Phase 3 will
involve conducting a qualitative postintervention follow-up study to better understand participants’ experiences
and perceived utility of the tool and readiness to adopt the tool at the point of care.
Discussion: The osteoporosis tool has the potential to make several contributions to the development and
evaluation of complex, chronic disease interventions, such as the inclusion of an implementation strategy prior to
conducting an evaluation study. Anticipated benefits of the tool may be to increase awareness for patients about
osteoporosis and its associated risks and provide an opportunity to discuss a management plan with their
physician, which may all facilitate patient self-management.
Background
There are over 200 million people worldwide who have
osteoporosis, representing a considerable healthcare and
financial burden [1-5]. The disease burden will be further
compounded by an increasingly aging population, which
will likely lead to more people who will suffer from
osteoporosis [2,3,6]. The clinical consequence of osteo-
porosis is fragility fractures; vertebral and hip fractures
have the most devastating prognosis [7] and are asso-
ciated with an increased risk of death [8]. Furthermore,
these fractures can significantly impair quality of life,
physical function, and social interaction and can lead to
admission to long-term care [9-11]. Although guidelines
are available for osteoporosis disease management
[12-14], many patients are not receiving appropriate diag-
nostic testing or treatment [15-19]. Clinical decision sup-
port systems (CDSSs) may be one solution to closing
these practice gaps because they can provide evidence at
the point of care to facilitate disease management. CDSSs
work by generating patient-specific assessments or
recommendations for clinicians; software algorithms
match pieces of information from a knowledge database
to relevant clinical data [20-22].
To determine what features of osteoporosis tools sup-
port clinical decision making in osteoporosis disease man-
agement, we conducted a systematic review of randomized
controlled trials [23]. Findings showed that interventions
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physicians and patients were more promising for increas-
ing osteoporosis investigations and treatment than single-
component or single-target interventions [23]. We first
developed a conceptual design for an osteoporosis disease-
management tool using these findings and input from
clinicians and experts in information technology and
human-factors engineering. We then built a prototype
using findings from a qualitative study of focus groups
with family physicians [24]. The prototype was further
refined in a series of usability studies with its target end
users (physicians and patients at risk for osteoporosis)
[25]. The osteoporosis tool is targeted to family physicians,
and patients at risk for osteoporosis (women age ≥50
years, men age ≥65 years) and consists of three compo-
nents: (1) a short (three to five minutes) electronic risk
assessment questionnaire (RAQ) targeted to at-risk
patients to be completed on a touch-screen tablet PC in
the clinic examination room (while they wait for their phy-
sician); (2) a one-page best practice recommendation
prompt (BestPROMPT) outlining appropriate osteoporosis
disease-management recommendations (e.g.,t oi n i t i a t e
bone mineral density [BMD] testing and osteoporosis
treatment) customized according to patients’ RAQ
responses and available to physicians in the few minutes
before the visit; (3) and a one-page, customized
osteoporosis education (COPE) sheet tailored to patients’
RAQ responses and given at the end of their physician
visit. The functional osteoporosis tool is accessible online
at http://knowledgetranslation.ca/osteo_final/index.html.
The objectives of the current study are to implement the
osteoporosis tool prototype in three family practice set-
tings and to conduct a pilot evaluation study to test the
impact of the osteoporosis tool on disease management
(i.e., appropriate initiation of osteoporosis investigations
and medications) using the quasi-experimental ITS design.
Specifically, we will answer the following questions: (1)
Does use of an osteoporosis disease-management tool by
family physicians lead to enhanced osteoporosis manage-
ment according to current clinical practice guidelines, as
measured by increased BMD testing and prescription of
osteoporosis medications such as bisphosphonates?; (2)
How do clinicians perceive the utility of the tool for chan-
ging clinical practice and knowledge uptake?; (3) What is
the impact of the tool on clinician adoption and satisfac-
tion with the tool?; (4) Do family physicians use the tool in
similar ways across different practice settings (e.g.,s o l o
practice vs. group practice)?
Methods
The osteoporosis tool will be evaluated according to a
three-phase process (see Figure 1): implementation of
Figure 1 The osteoporosis tool will be evaluated according to a three-phase process: implementation of the osteoporosis prototype in
three family practices (phase 1), evaluation of the tool using an ITS design (phase 2), and a qualitative evaluation to identify the barriers to using
the tool in practice (phase 3).
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(phase 1), evaluation of the tool using an ITS design
(phase 2), and a qualitative evaluation to identify the
barriers to using the tool in practice (phase 3).
Phase 1: implementation of the osteoporosis tool
The tool will be implemented in three family practice
settings selected purposively from the Hamilton Family
Health Team (FHT). This is the largest of the 150
approved primary care FHTs in Ontario, Canada, ser-
ving approximately 250,000 people [26]. It includes a
comprehensive team of healthcare professionals, includ-
ing 129 family physicians, 114 nurses and nurse practi-
tioners, 20 registered dieticians, 77 mental health
counsellors, 22 psychiatrists, and 7 pharmacists. A
unique feature of this FHT is that all physicians use an
electronic patient record system, although not every
physician uses the same system [26]. We purposively
selected three family practices (two solo and one group
practice) that used the same electronic medical record
(EMR) system (i.e., PracticeSolutions
® [Practice Solu-
tions, Ottawa, Ontario, Canada]) to facilitate implemen-
tation of the osteoporosis tool and subsequent data
collection during the evaluation study.
To ensure optimal functioning of the prototype and to
minimize disruption to usual practice, the osteoporosis
tool will be tailored to the practice and workflow of each
practice setting. We will complete a workflow analysis in
these family practice settings to ensure the prototype’s
optimal functioning, minimize the disruption of the tool
on usual practice, and determine if the tool could be
used by patients and physicians at the point of care. Our
previous work revealed that workflow differences needs
to be considered during the tool design process [24,25],
particularly for complex interventions that are delivered
at the point of care.
First, we will perform a workflow analysis, which will
include observation of clinic staff during “typical” clinic
days. Two researchers will document the patient registra-
tion process (particularly how patients are moved from
the waiting area to the examination room) and estimate
the average time that patients wait for their physician, the
length of patient visits, and time between visits. Second,
researchers and an information technologist will conduct
an environmental scan to ensure appropriate equipment
installation. Third, a procedures manual will be developed
and customized for each site. Lastly, clinic staff (including
physicians, nurses, and receptionists) will be trained on
how to use and troubleshoot the osteoporosis tool. Once
programming is completed and equipment installed,
clinics will be instructed to begin using the tool, and
observed to correct unanticipated installation, program-
ming, or workflow interruption problems. We will con-
sider the tool as implemented when no new problems are
reported for at least one week.
Phase 2: pilot evaluation study
Study design
The osteoporosis tool will be evaluated in a pilot study
using the quasi-experimental ITS design. Quasi-experi-
mental designs such as the ITS are particularly strong
alternatives to randomized controlled trials (RCTs) [27]
and are considered a useful and pragmatic tool, particu-
larly for pilot studies where initial evaluations of interven-
tions and their refinement need to be done before the
testing of the tool on a wider scale is justified [27,28].
Results from ITS studies can serve to inform the investiga-
tion of mediating factors (for example, if the intervention
i sf o u n dt ob em o r ee f f e c t i v ea to n es i t eb u tn o ta t
another), and they allow for the statistical investigation of
potential biases in the estimate of the effect of the inter-
vention [27,28]. For example, this design can address secu-
lar trends (i.e., the outcome may be increasing or
decreasing over time), history (i.e., there may be trends or
seasonal/cyclical observations over time), random fluctua-
tions with no discernable patterns, and autocorrelation
(i.e., the extent to which data collected close together in
time are correlated with each other) [27].
Sampling and population
In ITS studies, sample size calculations are related to the
estimation of the number of observations or time points at
which data will be collected. According to Ramsey et al.’s
quality criteria for ITS designs, at least 10 pre- and 10
post-data points would be needed to reach at least 80%
p o w e rt od e t e c tac h a n g e( i ft h ea u t o c o r r e l a t i o ni s> 0 . 4 )
[27]. Since the current study is a pilot, it is not known
what the autocorrelation might be or what effect size the
intervention is likely to produce. We therefore decided to
use a relatively large number of data points to ensure that
any trend or seasonal differences can be detected: 52 data
points per site (where one data point = two-week seg-
ment)–26 data points before the introduction of the inter-
vention (equivalent to 12 months’ worth of two-week
segments) and 26 data points after the introduction of the
intervention (two-week segments for 12 months). Partici-
pants will be family physicians practicing in a solo or
group practice within the Hamilton FHT and their
patients at risk for osteoporosis selected according to gen-
der- and age-eligibility criteria (i.e.,w o m e n≥50 years of
age, men ≥65 years of age).
Outcomes
Primary outcomes will be the initiation of appropriate
osteoporosis investigations (i.e., BMD testing) and treat-
ment (e.g., bisphosphonates, nutritional supplements
such as calcium and vitamin D) during a patient visit.
“Appropriate” osteoporosis management is defined as
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tice guidelines from Osteoporosis Canada [12] and is
represented by a disease-management algorithm pro-
grammed into the osteoporosis tool. Secondary out-
comes will include fractures, the reason for the visit,
number of patients who successfully complete the RAQ
(defined as an electronic log generated by the tablet PC
from patient-initiated RAQs), the mean time for patients
to complete the RAQ, and the mapping of an osteo-
porosis care model for patients who will complete the
RAQ (i.e., documentation of what physicians do during
the visit and subsequent visits with patients). Chart
review will also consist of extraction of site-specific
data, including the number of age-eligible patients/prac-
tice who had at least one visit during the intervention
period, the number of patients who are at risk for osteo-
porosis, and the mean number of patients who were
seen by their family physician within a two-week
segment.
Unit of analysis and data collection
Our unit of analysis will be based on the multiple base-
line assessment of individual family practice sites rather
than a single group of participants being tested repeat-
edly before and after the introduction of the interven-
tion. The data set at each time point will consist of
patient charts, which will represent the “episode of care”
used to extract outcome data for the study. To ensure
the completeness and validity of the data set at each
time point, we will apply the quality-control criteria of
ITS designs by Ramsay et al., which recommend that
80%-100% of the total number of episodes of care (i.e.,
patient charts) be used in the data collection [27].
Once the intervention is implemented, data will be
collected on all outcomes from electronic patient
records (i.e., PracticeSolutions
®) and the touch-screen
tablet PCs. The purpose of the pre-intervention chart
review will be to establish a stable baseline of standard
practice for each site. Visit-specific data (e.g.,i n i t i a t i o n
of osteoporosis disease management, reason for visit)
will be collected bimonthly at each site by two research-
ers (MK and CM). To minimize the introduction of
contamination that could bias results during this phase,
all data collection techniques, procedures, and data col-
lection forms will be standardized. For calibration of
reliability, these two researchers will extract data from
10 randomly selected patient charts in duplicate until
their agreement reaches ≥80%, at which point they will
abstract data independently. The two researchers will
collect data from the touch-screen tablet PCs, which
will automatically generate two electronic logs each time
a patient completes the RAQ. The first log will outline
dated/timed RAQ responses, and the other will sum-
marize the content of the BestPROMPT sheet. These
electronic logs will be matched against patient-visit
chart data to verify the use of the tool during the visit
and to map any actions taken by the physician in
response to the use of the RAQ.
Analysis
R e s u l t so ft h i sI T Ss t u d yw i l lf o c u so nt h ei m p a c to ft h e
intervention on the time series, which will be tested by
comparing pre- and postintervention segments of the
time series to estimate the magnitude and form of the
impact. “Impact” on practice will be defined according to
the level of change that is observed between the baseline
and postintervention periods of the study. The impact of
the tool for changing practice and satisfaction with the
tool will also be analyzed across the three sites. Aggre-
gated data from each two-week segment period on pri-
mary outcomes will be analyzed using the autoregressive
integrated moving average (ARIMA) approach and time-
series regression models [28,29]. We hypothesize that the
26 time-point baseline assessment of practice will show
no pre-intervention trend. The ARIMA approach will
estimate the extent to which a significant level of change
occurs between the pre-intervention and postinterven-
tion phases of the study. The multiple measurement
points are necessary for the ARIMA analysis to distin-
guish between treatment effects and secular trends. The
advantage of using the ARIMA approach for analysis is
that it accounts for the three major sources of noise that
may confound the analysis: trend, seasonality, and ran-
dom error [28,29]. Secondary outcomes and logs of
patient-initiated data from tablet PCs will be analyzed
using frequency analysis of site-specific data, descriptive
and inferential statistics to calculate proportions and
time to completion of the RAQ (e.g.,m e a n sw i t hs t a n -
dard deviations), and independent-sample t-tests or ana-
lysis of variance (ANOVA) for group comparisons (e.g.,
differences between sites for outcomes).
Phase 3: qualitative postintervention follow-up study
After the 12-month intervention phase, we will conduct
focus groups and interviews with participants of the
pilot study (family physicians, nurse practitioners, and
clinic staff from each site). The objectives of this study
will be to better understand participants’ experiences
with and perceived utility of the tool, readiness to adopt
the tool at the point of care, and satisfaction with its
implementation and use in practice. This information
will inform sustained use of the tool.
Methods
Focus groups and interviews will be conducted to pro-
voke an informal discussion about participants’ experi-
ences and satisfaction with the osteoporosis tool and to
find out their readiness to sustain the tool in their prac-
tice. Questions will include participants’ perceptions on
barriers and facilitators to using the osteoporosis tool at
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whether they plan to continue using the tool in their
practice, their perceptions of the tool’s impact on their
practice workflow, and any suggestions for improving
the tool. To minimize the occurrence of “history” (a
threat to internal validity where some other influential
event may happen during the intervention), we will
design an accompanying questionnaire to capture all
clinical practice-related activities done by physicians
(e.g., continuing medical education [CME] activities)
during the study that might account for changes
between baseline and postintervention observations. We
will also incorporate participant- and site-specific demo-
graphic questions and relevant items from the four-
point BARRIERS scale, which can be used to assess
barriers to research utilization [30].
Analysis
Interviews and accompanying questionnaires will be
quantitatively and qualitatively analyzed. Interview ses-
sions will be audiotaped and transcribed verbatim. Data
collection and qualitative content analyses will be guided
by the constant comparative method of grounded theory
methodology [31]. Two investigators will independently
develop a coding scheme by identifying, classifying, and
labelling the primary patterns in the content. Inter-
coder reliability will be assessed using Kappa statistics,
and any disagreements will be resolved by consensus.
Data will be coded from transcripts using a process of
open, axial, and selective coding [31,32] using NVivo 8
software (QSR International, Cambridge, MA, USA).
During open coding, the constant comparative approach
will be used to group the codes into categories and
identify themes. Quantitative analysis of accompanying
questionnaire data will be analyzed using analysis of var-
iance for continuous variables (e.g., Likert-type ques-
tions), chi-square tests for dichotomous variables (e.g.,
yes/no-type questions), and content analysis for open-
ended questions.
Discussion
The osteoporosis tool has the potential to impact clinical
care and to make several contributions to the development
of complex, chronic disease interventions. The clinical
goal of the osteoporosis tool was to bridge the gap
between current and best practice in osteoporosis disease
management. The three-phased evaluation study will
address this goal and illustrate how its rigorous develop-
ment can lead to meeting the many challenges to develop-
ing complex interventions. Without careful consideration
of system design, function, and end-user perspectives,
these interventions can fail [33]. If information technology
systems such as the osteoporosis tool are integrated with-
out evaluating how they might impact end users or their
existing workflow, they have the potential to be ineffective,
function poorly, and result in medical or technology-
induced errors [34-36]. To meet the specific needs of phy-
sicians, customization of information technology systems
such as the osteoporosis tool need to match and support
the workflow.
We anticipate that the osteoporosis tool will benefit
both physicians and patients. This benefit may include an
increased awareness for patients about osteoporosis and
its associated risks, the availability of relevant information
about what they can do about these risks, and the oppor-
tunity to discuss this information and a management
plan with their family physician at the point of care. We
believe that this component is an important step toward
improved self-management.
Self-management strategies can help patients manage
their medical conditions and provide patients with infor-
mation, skills, and the confidence (self-efficacy) to deal
with their illness [37]. Moreover, patient self-management
may facilitate the sustainability of an intervention by alle-
viating resource burdens that might be needed to maintain
the ongoing use of the tool; for example, a study found
that a falls-and-fractures prevention strategy in a family
practice unit delivered by clinic nurses was effective, but it
could not be sustained beyond the study period [38]. We
have planned for the equipment (touch-screen tablets,
printers, etc.) to remain at the evaluation sites perma-
nently so that patients and physicians can continue to ben-
efit from the tool beyond the study period if they choose
to.
Self-management is becoming increasingly important for
the development of chronic disease-management interven-
tions because seniors are becoming the fastest-growing
population group [39]. This is expected to increase the
prevalence of chronic diseases [40] and increase the aware-
ness and the need for patient self-care to support chronic
disease management [40,41]. As a result, there is a shift
toward a new patient-physician relationship for chronic
disease management, where patients are becoming their
own caregivers and healthcare professionals act as consul-
tants to support their patients in this role [42,43].
Potential limitations
Our study has several potential limitations. The ITS
methodology, which was chosen for the pilot evaluation
of the osteoporosis disease-management tool, is suscepti-
ble to several potential threats to internal validity. In gen-
eral, we designed our methodology according to the ITS
quality criteria recommended by Ramsay et al. to help
overcome these threats and to rule out any alternative
explanations of our findings [27]. Instrumentation (a
threat to internal validity that could occur if the measure-
ment method changes during the intervention and eva-
luation period) is a common threat in medical record
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come this problem, we will ensure that our databases,
recording systems, observers, and outcome-measure
instruments remain consistent, and they will be moni-
tored closely for any changes that might occur over the
course of the study. History is another potential threat
because a change in clinical practice independent of the
introduction of the intervention may occur from the
influence or participation of other events and activities
during the study period. For healthcare professionals and
physicians in particular, these include continuing profes-
sional development activities (e.g., participation in CME
activities such as didactic lectures, small-group work-
shops, and attendance at conferences). To address this
potential threat, we will collect information on continu-
ing professional development activities using the demo-
graphic/evaluation questionnaire, which will incorporate
questions targeted specifically for capturing clinical prac-
tice-related activities and events that might account for
changes between baseline and postintervention
observations.
Control of the implementation of the intervention
We anticipate that once the intervention is implemen-
ted, there will be an increase trend toward optimal prac-
tice according to guidelines. This sudden rise will likely
occur from the implementation process rather than the
intervention itself. We therefore chose a greater number
of data points (which is also equal to the data points in
the baseline assessment phase) to help neutralize the
initial impact of the implementation and allow the true
impact of the intervention to emerge.
Instability
Although the ITS design is susceptible to fluctuating
trends and cycles, most of these unpredictable elements
can be controlled statistically. We will use the ARIMA
approach to analyze our data to control for the effects
of variability. Additionally, we will also ensure that any
variability that may occur will not be due to unreliability
of the measurements (i.e., outcomes will be measured
objectively and assessed blindly). Lastly, the ITS metho-
dology largely limits the generalizability of its findings
[44]. However, the ITS design is a useful and pragmatic
tool, particularly for pilot studies where initial evalua-
tions of interventions and their refinement need to be
done before the testing of the tool on a wider scale is
justified. Furthermore, results from ITS studies can
serve to inform the investigation of mediating factors
(for example, if the intervention is found to be more
effective in one site but not in another) as well as more
extensive tests of their replicability in a randomized con-
trolled trial.
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